Tumor Biology

, Volume 36, Issue 12, pp 9259–9265 | Cite as

Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses

  • Ugo Borges Pinheiro
  • Carlos Alberto de Carvalho Fraga
  • Danilo Cangussu Mendes
  • Lucyana Conceição Farias
  • Cláudio Marcelo Cardoso
  • Christine Mendes Silveira
  • Marcos Flávio Silveira Vasconcelos D̕Angelo
  • Kimberly Marie Jones
  • Sérgio Henrique Souza Santos
  • Alfredo Maurício Batista de Paula
  • André Luiz Sena Guimarães
Research Article


It is estimated that 7.6 million people will die as a consequence of head and neck squamous cell carcinoma (HNSCC). Genetic predisposition has emerged as an important risk factor in the development and prognosis of HNSCC. Considering this, the aim of the current study is to assess whether codon 72 SNP of the TP53 gene (rs1042522) is associated with an increased odds ratio of developing HNSCC or with a worse prognosis in patients with HNSCC. Analysis of the rs1042522 in HNSCC patients and in control individuals. Differences between the case and control groups were determined using chi-squared tests. Multivariate analysis was performed to evaluate the odds ratio of HNSCC. Fussy C Means Clustering was to cluster HNSCC patients for survival analyses. Time of survival was calculated using the Kaplan-Meier estimator and comparing this to the log rank test. Statistical significance was set at p < 0.05. A total of 71.4 % of the Arg/Arg genotype were from HNSCC patients, while only 28.6 % of Arg/Arg genotype were found in the control group. Logistic regression demonstrated that the Arg/Arg genotype, smoking, and alcohol consumption increase the odds ratio of HNSCC. No association between TP53 codon 72 polymorphism and P53 expression. No association between rs1042522 and survival or prognoses was observed. This study identified that individuals carrying the arginine allele at rs1042522 have an increased odds ratio of HNSCC. However, no association between codon 72 SNP of the TP53 gene and HNSCC prognosis or P53 expression was observed.


Tumor suppressor gene Survival Oral cancer Survival p53 



This study was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and the Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG). Dr.Guimarães, Dr. Santos, and Dr. de Paula are research fellows of the CNPq.

Supplementary material

13277_2015_3677_Fig3_ESM.gif (17 kb)
Supplementary Figure 3

Survival of HNSCC patients according to TNM. The results of the Kaplan-Meier estimator were compared to the log rank test. (A) was without Fuzzy C Means clustering (p = 0.03) and (B) was with Fuzzy C Means clustering (p = 0.02) (GIF 16 kb)

13277_2015_3677_MOESM1_ESM.tif (11.8 mb)
(TIFF 12080 kb)
13277_2015_3677_MOESM2_ESM.doc (110 kb)
ESM 1 (DOC 109 kb)
13277_2015_3677_MOESM3_ESM.doc (30 kb)
ESM 2 (DOC 30 kb)


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    (INCA) NCI: Estimate 2014: Brazilian cancer incidence.: Instituto Nacional deCâncer. 2014.Google Scholar
  3. 3.
    De Paula AM, Souza LR, Farias LC, Correa GT, Fraga CA, Eleuterio NB, et al. Analysis of 724 cases of primary head and neck squamous cell carcinoma (hnscc) with a focus on young patients and p53 immunolocalization. Oral Oncol. 2009;45:777–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev. 2005;24:9–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Gritz ER, Carr CR, Rapkin DA, Chang C, Beumer J, Ward PH. A smoking cessation intervention for head and neck cancer patients: trial design, patient accrual, and characteristics. Cancer Epidemiol Biomark Prev. 1991;1:67–73.Google Scholar
  6. 6.
    Wang JR, Gramling SJ, Goldstein DP, Cheng D, Chen D, Azad AK, et al. Association of two brm promoter polymorphisms with head and neck squamous cell carcinoma risk. Carcinogenesis. 2013;34:1012–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Thakur N, Hussain S, Nasare V, Das BC, Basir SF, Bharadwaj M. Association analysis of p16 (cdkn2a) and rb1 polymorphisms with susceptibility to cervical cancer in indian population. Mol Biol Rep. 2012;39:407–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Fonseca-Silva T, Oliveira MV, Fraga CA, Farias LC, Gomes EP, Barros LO, et al. Dnmt3b (c46359t) polymorphisms and immunoexpression of dnmt3b and dnmt1 proteins in oral lichen planus. Pathobiology. 2012;79:18–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Alves LR, Fraga CA, Oliveira MV, Sousa AA, Jorge AS, Marques-Silva L, et al. High hif-1alpha expression genotypes increase odds ratio of oral cancer. Head Neck Oncol. 2012;4:87.Google Scholar
  10. 10.
    Fraga CA, Sousa AA, Correa GT, Jorge AS, Jesus SF, Jones KM, et al. High hypoxia-inducible factor-1alpha expression genotype associated with eastern cooperative oncology group performance in head and neck squamous cell carcinoma. Head Neck Oncol. 2012;4:77.Google Scholar
  11. 11.
    Dutra RL, de Carvalho MB, Dos Santos M, Mercante AM, Gazito D, de Cicco R, et al. Fgfr4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One. 2012;7:e50747.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, et al. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg. 2011;253:918–27.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen J, Li D, Wei C, Sen S, Killary AM, Amos CI, et al. Aurora-a and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in caucasians. Clin Cancer Res. 2007;13:3100–4.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zheng Y, Shen H, Sturgis EM, Wang LE, Shete S, Spitz MR, et al. Haplotypes of two variants in p16 (cdkn2/mts-1/ink4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev. 2002;11:640–5.PubMedGoogle Scholar
  15. 15.
    Stefani FA, Viana MB, Dupim AC, Brito JA, Gomez RS, da Costa JE, et al. Expression, polymorphism and methylation pattern of interleukin-6 in periodontal tissues. Immunobiology. 2012;218:2012–7.Google Scholar
  16. 16.
    Dutra WO, Moreira PR, Souza PE, Gollob KJ, Gomez RS. Implications of cytokine gene polymorphisms on the orchestration of the immune response: Lessons learned from oral diseases. Cytokine Growth Factor Rev. 2009;20:223–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Correa GT, Bandeira GA, Cavalcanti BG, de Carvalho Fraga CA, Dos Santos EP, Silva TF, et al. Association of -308 tnf-alpha promoter polymorphism with clinical aggressiveness in patients with head and neck squamous cell carcinoma. Oral Oncol. 2011;47:888–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Farias LC, Fraga CA, De Oliveira MV, Silva TF, Marques-Silva L, Moreira PR, et al. Effect of age on the association between p16cdkn2a methylation and dnmt3b polymorphism in head and neck carcinoma and patient survival. Int J Oncol. 2010;37:167–76.PubMedGoogle Scholar
  19. 19.
    McBride OW, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A. 1986;83:130–4.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Soussi T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep. 2010;11:822–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Muller PA, Vousden KH. P53 mutations in cancer. Nat Cell Biol. 2013;15:2–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Xu T, Xu ZC, Zou Q, Yu B, Huang XE. P53 arg72pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in asians but not caucasians. Asian Pac J Cancer Prev. 2012;13:2349–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. Tp53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–84.CrossRefPubMedGoogle Scholar
  24. 24.
    Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol. 2004;164:1233–41.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Fraga CA, de Oliveira MV, de Oliveira ES, Barros LO, Santos FB, Gomez RS, et al. A high hif-1alpha expression genotype is associated with poor prognosis of upper aerodigestive tract carcinoma patients. Oral Oncol. 2012;48:130–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Bezdek JC. Pattern recognition with fuzzy objective function algorithms. New York: Plenum Press; 1981.CrossRefGoogle Scholar
  28. 28.
    Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Tp53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Cadoni G, Boccia S, Petrelli L, Di Giannantonio P, Arzani D, Giorgio A, et al. A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism. Acta Otorhinolaryngol Ital. 2012;32:1–11.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Correa GT, Bandeira GA, Cavalcanti BG, Santos FB, Neto JF, Guimaraes AL, et al. Analysis of ecog performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012;20:2679–85.CrossRefPubMedGoogle Scholar
  31. 31.
    Suresh K, Chandirasekar R, Kumar BL, Venkatesan R, Sasikala K. No association between the trp53 codon 72 polymorphism and head and neck cancer: a case-control study in a south indian population. Asian Pac J Cancer Prev. 2010;11:1749–53.PubMedGoogle Scholar
  32. 32.
    Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183:123–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the arg allele is preferentially retained in tumours arising in arg/pro germline heterozygotes. Br J Cancer. 2002;87:1013–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Brant O, Hoffmann M, Kanappilly A, Gorogh T, Gottschlich S. P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. Anticancer Res. 2007;27:3301–5.PubMedGoogle Scholar
  35. 35.
    Ferreira da Silva I, Koifman RJ, Quinto Santos Souza C, Ferreira de Almeida Neto O, Koifman S. Tp53 genetic polymorphisms and environmental risk factors associated with cervical carcinogenesis in a cohort of brazilian women with cervical lesions. J Toxicol Environ Health A. 2010;73:888–900.CrossRefPubMedGoogle Scholar
  36. 36.
    Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of mdm2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19–27.CrossRefPubMedGoogle Scholar
  37. 37.
    Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.CrossRefPubMedGoogle Scholar
  38. 38.
    Jing G, Lv K, Jiao X. The p53 codon 72 polymorphism and the risk of oral cancer in a chinese han population. Genet Test Mol Biomarkers. 2012;16:1149–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Jiang M, Chiu SY, Hsu W. Sumo-specific protease 2 in mdm2-mediated regulation of p53. Cell Death Differ. 2011;18:1005–15.CrossRefPubMedGoogle Scholar
  40. 40.
    Linder S, Parrado C, Falkmer UG, Blasjo M, Sundelin P, von Rosen A. Prognostic significance of ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: a study of the monoclonal antibodies mib-1 and do-7 in formalin-fixed paraffin-embedded tumour material. Br J Cancer. 1997;76:54–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Shinohara S, Kikuchi M, Tona R, Kanazawa Y, Kishimoto I, Harada H, et al. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas. Jpn J Clin Oncol. 2014;44:232–40.CrossRefPubMedGoogle Scholar
  42. 42.
    de Oliveira MV, Pereira Gomes EP, Pereira CS, de Souza LR, Barros LO, Mendes DC, et al. Prognostic value of microvessel density and p53 expression on the locoregional metastasis and survival of the patients with head and neck squamous cell carcinoma. Appl Immunohistochem Mol Morphol: AIMM / Off Publ Soc Appl Immunohistochem. 2013;21:444–51.CrossRefGoogle Scholar
  43. 43.
    Wang Z, Sturgis EM, Guo W, Song X, Zhang F, Xu L, et al. Association of combined p73 and p53 genetic variants with tumor hpv16-positive oropharyngeal cancer. PLoS One. 2012;7:e35522.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, et al. Biomarkers of hpv in head and neck squamous cell carcinoma. Cancer Res. 2012;72:5004–13.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23:3328–37.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ugo Borges Pinheiro
    • 1
  • Carlos Alberto de Carvalho Fraga
    • 1
  • Danilo Cangussu Mendes
    • 1
  • Lucyana Conceição Farias
    • 1
  • Cláudio Marcelo Cardoso
    • 2
  • Christine Mendes Silveira
    • 2
  • Marcos Flávio Silveira Vasconcelos D̕Angelo
    • 3
  • Kimberly Marie Jones
    • 4
  • Sérgio Henrique Souza Santos
    • 5
  • Alfredo Maurício Batista de Paula
    • 1
  • André Luiz Sena Guimarães
    • 1
  1. 1.Department of DentistryUniversidade Estadual de Montes ClarosMontes ClarosBrazil
  2. 2.Department of Medicine and Department of Computer ScienceUniversidade Estadual de Montes ClarosMontes ClarosBrazil
  3. 3.Universidade Estadual de Montes ClarosMontes ClarosBrazil
  4. 4.Center for ResearchThe Educative Association of BrazilMontes ClarosBrazil
  5. 5.Department PharmacologyUniversidade Federal de Minas GeraisBelo HorizonteBrazil

Personalised recommendations